Judmaier G, Koelz H R
University Hospital, Innsbruck, Austria.
Aliment Pharmacol Ther. 1994 Feb;8(1):81-6. doi: 10.1111/j.1365-2036.1994.tb00163.x.
Pantoprazole is a new substituted benzimidazole that blocks the H+/K(+)-ATPase in the gastric mucosa and thus inhibits acid secretion.
Efficacy and tolerability of pantoprazole (40 mg at breakfast) and ranitidine (300 mg at bedtime) in the treatment of uncomplicated acute duodenal ulcer were compared in a double-blind randomized multicentre trial.
Of 202 outpatients who entered the study, 185 terminated the treatment without violation of the protocol. After 2 weeks of treatment, healing rates (protocol correct) with pantoprazole and ranitidine were 81 and 53%, respectively (P < 0.001), the corresponding results after 4 weeks were 97 and 83% (P < 0.01). Pantoprazole was more effective with respect to symptom relief. Both treatments were well tolerated.
Pantoprazole 40 mg at breakfast is superior to ranitidine 300 mg at bedtime in the short-term treatment of acute, uncomplicated duodenal ulcer.
泮托拉唑是一种新型取代苯并咪唑,可阻断胃黏膜中的H⁺/K⁺-ATP酶,从而抑制胃酸分泌。
在一项双盲随机多中心试验中,比较了泮托拉唑(早餐时服用40毫克)和雷尼替丁(睡前服用300毫克)治疗单纯性急性十二指肠溃疡的疗效和耐受性。
202名进入研究的门诊患者中,185名未违反方案终止治疗。治疗2周后,泮托拉唑和雷尼替丁的愈合率(符合方案)分别为81%和53%(P<0.001),4周后的相应结果为97%和83%(P<0.01)。泮托拉唑在缓解症状方面更有效。两种治疗耐受性均良好。
早餐时服用40毫克泮托拉唑在急性单纯性十二指肠溃疡的短期治疗中优于睡前服用300毫克雷尼替丁。